Healthcare / Medical DevicesBSE
$393.80
+7.20 (+1.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-329.4M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
58/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.7B
P/E
27.5x
↑EV/EBITDA
17.9x
↑ROE
13.2%
↑Gross Margin
23.0%
↓Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+28.5%
FCF CAGR
—
FCF margin
-14.7%
FCF / Net income
-1.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.32B · net income $181.9M · FCF $-341.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.32B | $2.32B | $1.07B | $1.06B | $1.09B |
| Net Income | $181.9M | $181.9M | $80.4M | $98.0M | $76.4M |
| EBITDA | $290.9M | $290.9M | $141.0M | $147.8M | $129.0M |
| EPS | — | — | 7.70 | 9.85 | 7.32 |
| Gross Margin | 23.0% | 23.0% | 29.0% | 24.7% | 24.7% |
| Operating Margin | 9.4% | 9.4% | 7.1% | 9.3% | 8.9% |
| Net Margin | 7.8% | 7.8% | 7.5% | 9.3% | 7.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.36 | 0.36 | 0.49 | 0.12 | 0.30 |
| Current Ratio | 1.45 | 1.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-341.7M | $-341.7M | $-329.4M | $-130.8M | $23.7M |
| Returns | |||||
| ROE | 13.2% | 13.2% | 12.7% | 17.9% | 32.7% |
| Valuation | |||||
| P/E | 27.54 | 27.54 | 13.51 | 15.23 | — |
| EV/EBITDA | 17.85 | 17.85 | 9.40 | 9.66 | — |
| P/B | 3.73 | 3.73 | 1.72 | 2.72 | — |
| Growth & Yield | |||||
| Revenue Growth | 117.4% | 117.4% | 1.0% | -3.2% | — |
| EPS Growth | — | — | -21.8% | 34.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+282.3%
Start / end P/E
n/dx → n/dx
EPS bridge
7.70 → n/d
Residual
+282.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.